SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines administered by tablet rather than
by injection, today announced that Wouter Latour, M.D., president and
chief executive officer of Vaxart, will present a company overview at
the 17th Annual Needham Healthcare Conference on Wednesday, March 28,
2018, at 3:30 p.m. EST in New York.
A live webcast of the presentation will be available by visiting the
Investors section of Vaxart's website at investors.vaxart.com.
A replay of the webcast will be archived on Vaxart's website for 30 days
following the presentation.
About Vaxart
Vaxart is a clinical-stage company focused on developing oral
recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart's vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may be useful for the treatment of chronic viral infections
and cancer. Vaxart's vaccines are administered using a convenient room
temperature-stable tablet, rather than by injection. Vaxart believes
that tablet vaccines are easier to distribute and administer than
injectable vaccines, and have the potential to significantly increase
vaccination rates. Vaxart's development programs include oral tablet
vaccines that are designed to protect against norovirus, seasonal
influenza and respiratory syncytial virus (RSV), as well as a
therapeutic vaccine for human papillomavirus (HPV). Vaxart is also
developing several small-molecule antiviral drug candidates, including
teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV
types 6 and 11. For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, beliefs and expectations
of management are forward-looking statements. These forward-looking
statements may be accompanied by such words as "believe," "could,"
"potential" and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements relating to
the Vaxart's ability to develop and commercialize its product
candidates. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxart's product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxart's product candidates may not achieve broad market
acceptance; and the risks described in the "Risk Factors" sections of
the Registration Statement on Form S-4 (file no. 333-222009) and of
Vaxart's periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180321005338/en/
W2O
Katie Hogan, 415-658-9745
khogan@wcgworld.com
or
Stern
Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com
Source: Vaxart, Inc.
News Provided by Acquire Media